Le Gouill S, Beldi-Ferchiou A, Alcantara M, et al. - In mantle cell lymphoma, promising efficacy has been seen with obinutuzumab monotherapy, so researchers performed this prospective, open-label, single-arm, phase 2 trial (LyMa-101) with 86 newly diagnosed patients with mantle cell lymphoma (aged 18 to < 66 years) eligible for autologous stem-cell transplantation to determine the activity of obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin), evaluated by minimal residual disease quantitative (q)PCR status in the bone marrow following four cycles. In transplant-eligible patients suffering from mantle cell lymphoma, findings showed that, in addition to good tolerability, obinutuzumab plus DHAP displayed good activity for inducing minimal residual disease negativity in bone marrow. The potential activity of obinutuzumab plus DHAP as induction chemotherapy was suggested based on the findings, with bone marrow minimal residual disease negativity potentially predicting long-term disease control.